C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more
Market Cap & Net Worth: C-Rad AB (publ) (CRAD-B)
C-Rad AB (publ) (ST:CRAD-B) has a market capitalization of $74.02 Million (Skr830.39 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #20617 globally and #223 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying C-Rad AB (publ)'s stock price Skr25.85 by its total outstanding shares 32123311 (32.12 Million).
C-Rad AB (publ) Market Cap History: 2015 to 2026
C-Rad AB (publ)'s market capitalization history from 2015 to 2026. Data shows growth from $43.24 Million to $74.02 Million (3.93% CAGR).
C-Rad AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how C-Rad AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
C-Rad AB (publ)'s market cap is 0.21 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
8.71x
C-Rad AB (publ)'s market cap is 8.71 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $34.51 Million | $82.65 Million | -$31.21 Million | 0.42x | N/A |
| 2017 | $81.04 Million | $133.12 Million | -$10.91 Million | 0.61x | N/A |
| 2018 | $73.88 Million | $190.11 Million | $21.19 Million | 0.39x | 3.49x |
| 2019 | $127.43 Million | $205.39 Million | -$13.80 Million | 0.62x | N/A |
| 2020 | $138.02 Million | $221.63 Million | $14.37 Million | 0.62x | 9.61x |
| 2021 | $159.50 Million | $261.15 Million | $25.10 Million | 0.61x | 6.35x |
| 2022 | $109.10 Million | $301.33 Million | $7.48 Million | 0.36x | 14.59x |
| 2023 | $120.84 Million | $424.62 Million | $35.53 Million | 0.28x | 3.40x |
| 2024 | $85.91 Million | $469.00 Million | $56.45 Million | 0.18x | 1.52x |
| 2025 | $91.49 Million | $441.90 Million | $10.50 Million | 0.21x | 8.71x |
Competitor Companies of CRAD-B by Market Capitalization
Companies near C-Rad AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to C-Rad AB (publ) by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
C-Rad AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, C-Rad AB (publ)'s market cap moved from $43.24 Million to $ 74.02 Million, with a yearly change of 3.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr74.02 Million | -19.09% |
| 2025 | Skr91.49 Million | +6.50% |
| 2024 | Skr85.91 Million | -28.91% |
| 2023 | Skr120.84 Million | +10.76% |
| 2022 | Skr109.10 Million | -31.60% |
| 2021 | Skr159.50 Million | +15.56% |
| 2020 | Skr138.02 Million | +8.31% |
| 2019 | Skr127.43 Million | +72.48% |
| 2018 | Skr73.88 Million | -8.83% |
| 2017 | Skr81.04 Million | +134.85% |
| 2016 | Skr34.51 Million | -20.20% |
| 2015 | Skr43.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of C-Rad AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $74.02 Million USD |
| MoneyControl | $74.02 Million USD |
| MarketWatch | $74.02 Million USD |
| marketcap.company | $74.02 Million USD |
| Reuters | $74.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.